@FiercePharma: Tops in FiercePharmaManufacturing Tues: Boehringer Ingelheim recalls cancer drug made at ill-fated Bedford plant. Article | Follow @FiercePharma
@EricPFierce: Agents in EU seize €10M worth of counterfeit drugs, as well as cash and luxury cars, arrest a dozen. FiercePharmaManufacturing article | Follow @EricPFierce
@CarlyHFierce: Teva trounces patent on AstraZeneca's Symbicort, opening up U.K. copycat launch. Story | Follow @CarlyHFierce
> Roche ($RHHBY) will ax 100 jobs in Spain in a restructuring of its operations in the country, citing price controls as one motivating factor. Report
> Allergan ($AGN) has to face a shareholder lawsuit over allegedly improper Botox marketing, the Ninth Circuit Court of Appeals ruled, overturning a lower court's dismissal of the claims. Report
> Merck KGaA broke ground on another addition to its revamped Darmstadt, Germany, headquarters. Release
> U.K. cost-effectiveness watchdogs called for the country's Cancer Drugs Fund to adopt its framework for evaluating treatments. Report
> Armed with new data on brain shrinkage in multiple sclerosis patients, Novartis ($NVS) is calling for a new version of treatment goals. Report
> Iroko Pharmaceuticals said its new arthritis pain reliever Zorvolex won spots on key managed care formularies. Release
Medical Device News
@FierceMedDev: ICYMI: ArthroCare $750M fraud saga culminates in decades-long prison term. Article | Follow @FierceMedDev
@VarunSaxena2: Will little-known company's inhaled candidate take down InterMune-Roche's pirfenidone? FierceDrugDelivery story | Follow @VarunSaxena2
@MichaelGFierce: Artificial virus promises effective drug delivery and gene therapy. FierceDrugDelivery story | Follow @MichaelGFierce
@EmilyWFierce: Bionic eye bridges gap between visual signals and brain, gives blind patients a chance to see. More from The Atlantic | Follow @EmilyWFierce
> FDA clears wireless, vitals monitor patch that transmits to smartphone. Story
> J&J shoring up for latest courtroom battle over all-metal hip implant. Article
Biotech News
@FierceBiotech: $RHHBY CEO Schwan took a hands-on approach negotiating $8.3B $ITMN buyout. Report | Follow @FierceBiotech
@JohnCFierce: $GSK's new Boston collaboration chief goes 'anti-pharma' as he prowls for partners. Story | Follow @JohnCFierce
@DamianFierce: Steven Paul (former $LLY exec, $SAGE co-founder) takes the helm at Third Rock's Voyager Therapeutics. Release (PDF) | Follow @DamianFierce
@EmilyMFierce: Ebola treatments caught in limbo. More from Nature | Follow @EmilyMFierce
> Teva's well-traveled asthma drug comes through in Phase III. News
> Feds pledge up to $42M to hit the gas on Mapp's Ebola drug. More
> AbbVie ties the knot with Infinity in $805M blood cancer collaboration. Report
Drug Delivery News
> UO, Berkeley team tailors ultrathin peptoid nanosheets for delivery using oil and water. More
> RNAi pipeline active as investors, patients wait for commercialization. Item
> BioTime enters academic collaborations to advance its hydrogel for vocal fold scarring. Article
> Artificial virus promises effective drug delivery and gene therapy. Story
> Will little-known company's inhaled candidate take down InterMune-Roche's pirfenidone? Report
Diagnostics News
> Companion diagnostics crossed the billion-dollar threshold in 2013: Report. More
> Finnish gene sequencing Dx startup wins funding to back U.S. expansion. Report
> Quest scientists and others identify new rheumatoid arthritis biomarker. Item
> NanoString mourns the sudden death of its CMO. Story
> MIT discovers malaria parasitic waste has Dx biomarker potential. Article
Pharma Marketing News
> J&J, Bayer look to turbocharge Xarelto with new label-expanding studies. More
> Genzyme puts $310,250 price tag on new Gaucher-fighting pill. Article
> Actavis' Namenda switch exceeds expectations, and its ability to supply new version. Item
> GSK can't deep-clean its image overnight. But it can revamp its websites. Story
> Novartis sees 'most exciting launch' ever with megablockbuster-to-be heart drug. Report
And Finally... Should companies reimburse executives for special inversion-deal taxes? Report